Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PD-1 Progress May Shorten The Life Of Other Drugs

Executive Summary

With PD-1 immunotherapy continuing to make gains in melanoma, will Yervoy and targeted BRAF/MEK combos from Novartis, Roche and Array BioPharma get relegated to second-class status?

You may also be interested in...



Heat Biologics Tightens Belt To Reach Late-2016 Inflection Points

Biotech striving to hold on financially until it can deliver top-line data for bladder and lung cancer immunotherapy candidates, but then it will have to content with Roche entering the bladder cancer market with its PD-L1 inhibitor.

Genentech Catching Up In Melanoma With Cotellic Approval

FDA clears Cotellic/Zelboraf combination, but the company already is testing the addition of a PD-L1 inhibitor.

Bristol’s Opdivo Delay May Help It Beat Out BRAF Inhibitors

Firm announces three-month user fee extension for first-line melanoma claim for Opdivo, but the firm’s statement suggests a silver lining.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC010771

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel